Medicenna Therapeutics (MDNA) News Today C$0.92 -0.12 (-11.54%) As of 03/3/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Medicenna Therapeutics (TSE:MDNA) Sets New 1-Year Low - Time to Sell?Medicenna Therapeutics (TSE:MDNA) Reaches New 52-Week Low - Here's What HappenedMarch 1 at 9:10 PM | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Trading Down 1.7% - Here's What HappenedMedicenna Therapeutics (TSE:MDNA) Stock Price Down 1.7% - What's Next?February 26, 2025 | marketbeat.comMedicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11February 25, 2025 | markets.businessinsider.comMedicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated MilestonesFebruary 13, 2025 | uk.finance.yahoo.comMedicenna Therapeutics (TSE:MDNA) Stock Price Down 3.8% - Should You Sell?Medicenna Therapeutics (TSE:MDNA) Stock Price Down 3.8% - Should You Sell?February 4, 2025 | marketbeat.comMedicenna Therapeutics Corp. (TSE:MDNA) Senior Officer Acquires C$29,000.00 in StockJanuary 11, 2025 | insidertrades.comInsider Buying: Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer Buys 20,000 Shares of StockMedicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) Senior Officer David Hyman purchased 20,000 shares of the firm's stock in a transaction on Thursday, January 9th. The stock was bought at an average price of C$1.45 per share, for a total transaction of C$29,000.00.January 10, 2025 | marketbeat.comMedicenna’s MDNA11 Shows Promising Cancer Treatment ResultsDecember 6, 2024 | markets.businessinsider.comMedicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finanznachrichten.deMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finance.yahoo.comMedicenna Reports Promising Results with MDNA11November 12, 2024 | markets.businessinsider.comMedicenna Therapeutics (TSE:MDNA) Shares Up 5.2% - Still a Buy?Medicenna Therapeutics (TSE:MDNA) Trading 5.2% Higher - Should You Buy?October 25, 2024 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Trading Down 2.4% - Time to Sell?Medicenna Therapeutics (TSE:MDNA) Stock Price Down 2.4% - Should You Sell?October 4, 2024 | marketbeat.com3 Top Growth Companies With High Insider Ownership On The TSXSeptember 27, 2024 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual Meeting of ShareholdersSeptember 27, 2024 | finanznachrichten.deTop TSX Growth Companies With High Insider Ownership For September 2024September 19, 2024 | finance.yahoo.comMedicenna to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | tmcnet.comTop TSX Growth Companies With High Insider Ownership August 2024August 29, 2024 | finance.yahoo.com3 TSX Growth Companies With High Insider Ownership And Up To 47% Revenue GrowthAugust 20, 2024 | au.finance.yahoo.comMedicenna Therapeutics Corp. (MDNA)August 2, 2024 | finance.yahoo.comMedicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 MonotherapyAugust 1, 2024 | finance.yahoo.comMedicenna's MDNA11 And Bizaxofusp Show Strong Potential Despite DelistingJuly 22, 2024 | seekingalpha.comMedicenna (MDNA) Earnings Dates & ReportsMay 28, 2024 | investing.comMedicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation ForumMay 22, 2024 | finance.yahoo.comMedicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program CommitteeMay 13, 2024 | finance.yahoo.comMedicenna Provides Update on its Presentations at the 2024 ASCO Annual MeetingMay 13, 2024 | finance.yahoo.comNew Buy, Medicenna: Superkine Platform In OncologyMay 7, 2024 | seekingalpha.comCanadian Investment Regulatory Organization Trading Halt - MDNAApril 26, 2024 | ca.finance.yahoo.comMedicenna Therapeutics Announces CA$20 Million Investment from RA Capital ManagementApril 26, 2024 | finance.yahoo.comMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)April 9, 2024 | finance.yahoo.comMedicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)April 9, 2024 | finance.yahoo.comMedicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)March 27, 2024 | theglobeandmail.comMedicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual MeetingMarch 6, 2024 | finance.yahoo.comMedicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsFebruary 13, 2024 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finanznachrichten.deMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finance.yahoo.comAll You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to BuyNovember 20, 2023 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 14, 2023 | finanznachrichten.deMedicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingNovember 9, 2023 | finance.yahoo.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)October 24, 2023 | tmcnet.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)October 24, 2023 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerOctober 10, 2023 | finanznachrichten.deMedicenna Therapeutics (MDNA) Price Target Increased by 34.63% to 3.93October 5, 2023 | nasdaq.comMedicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapyOctober 3, 2023 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual and Special Meeting of ShareholdersSeptember 29, 2023 | finanznachrichten.deMedicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapySeptember 28, 2023 | finance.yahoo.comIs Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?September 26, 2023 | finance.yahoo.comMedicenna to Participate at The H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 6, 2023 | finance.yahoo.comMedicenna Therapeutics gets new CFOAugust 28, 2023 | msn.comMedicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerAugust 28, 2023 | finance.yahoo.com Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Email Address MDNA Media Mentions By Week MDNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDNA News Sentiment▼-0.330.70▲Average Medical News Sentiment MDNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDNA Articles This Week▼30▲MDNA Articles Average Week Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aimia News Fennec Pharmaceuticals News Andean Precious Metals News Cardiol Therapeutics News Gear Energy News Graphite One News International Tower Hill Mines News EQ News CI Canadian Convertible Bond ETF Common News BioRem News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:MDNA) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
